Budigalimab

DB16668InvestigationalProtein Based Therapies

Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV...

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Code names: ABBV-181 · Anti-PD1 monoclonal antibody ABBV-181 · PR-1648817

Resolves to

Compound

UNII6VDO4TY3OOCAS2098225-93-3

Targets

Q15116PDCD1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

28Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Budigalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account